Amyris up on partnership with ImmunityBio for COVID-19 vaccine commercialization

Amyris

08/11/2021 13:49

** Shares of biotechnology firm  AMRS.O  up ~1.6% at $14.32
pre-market
    ** Co announces 50:50 joint venture arrangement with
immunotherapy co ImmunityBio Inc  IBRX.O  to accelerate
commercialization of its COVID-19 RNA vaccine, currently under
development
    ** IBRX will be responsible for vaccine's manufacturing once
human trials being conducted in South Africa are successfully
completed 
    ** Amyris will provide its RNA technology licensed last year
from Infectious Disease Research Institute as well as an organic
compound used to produce the vaccine 
    ** Goal is to deliver one billion doses of the new vaccine
in 2022- AMRS  urn:newsml:reuters.com:*:nPn76tnNBa
    ** The vaccine "could reduce the dose needed and address
supply chain shortages" said Patrick Soon-Shiong Global Chief
Medical and Scientific Officer of IBRX
    ** Up to Friday's close, stock had risen 128.18% YTD 

    
    

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))